Lilly Shouldn't Return Sales From Now-Withdrawn Lartruvo, Gottlieb Says

Former US FDA Commissioner Scott Gottlieb said that despite the $500m Lilly took in from sales of Lartruvo, the company probably lost money with the costs of R&D and withdrawing the drug from the market.